Last reviewed · How we verify

PRGF/ATV

Ain Shams University · FDA-approved active Small molecule

PRGF/ATV is a platelet-rich growth factor combined with autologous tenocyte therapy designed to promote tissue regeneration and repair.

PRGF/ATV is a platelet-rich growth factor combined with autologous tenocyte therapy designed to promote tissue regeneration and repair. Used for Tendon injuries and degenerative conditions, Soft tissue repair and regeneration.

At a glance

Generic namePRGF/ATV
Also known asplatelets rich in growth factors
SponsorAin Shams University
Drug classAutologous cell/tissue therapy with growth factor concentrate
ModalitySmall molecule
Therapeutic areaOrthopedics / Regenerative Medicine
PhaseFDA-approved

Mechanism of action

PRGF (Plasma Rich in Growth Factors) is an autologous blood-derived product containing concentrated growth factors that stimulate healing and tissue regeneration. When combined with ATV (autologous tenocyte therapy), it leverages both the growth factor milieu and viable tenocytes to enhance tendon and soft tissue repair through paracrine signaling and direct cellular regeneration mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: